$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
BIOA • NASDAQ
| BioAge Labs, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
188.9M | 354.3M | 21.6M | 27.6M | |
92.2M | 0.0 | 0.0 | 0.0 | |
281.1M | 354.3M | 21.6M | 27.6M | |
769K | 0.0 | 0.0 | 0.0 | |
769K | 0.0 | 0.0 | 0.0 | |
4.9M | 2.8M | 3.7M | 386K | |
286.8M | 357.1M | 25.3M | 28M | |
NON-CURRENT ASSETS | ||||
3.7M | 791K | 518K | 374K | |
100K | 100K | 100K | 0.0 | |
4.2M | 240K | 0.0 | 25K | |
8.1M | 1.1M | 618K | 399K | |
294.9M | 358.2M | 25.9M | 28.4M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
2.7M | 2M | 1.9M | 2.3M | |
2.7M | 2M | 1.9M | 2.3M | |
0.0 | 11.3M | 6.5M | 3.4M | |
3.2M | 6M | 44.9M | 167K | |
0.0 | 202K | 194K | 49K | |
5.8M | 7.8M | 3.3M | 0.0 | |
8.5M | 417K | 1.4M | 24K | |
20.1M | 27.8M | 58.2M | 5.9M | |
NON-CURRENT LIABILITIES | ||||
2.3M | 2.5M | 8.2M | 2.3M | |
0.0 | 4.7M | 0.0 | 0.0 | |
370K | 156K | 133M | 132.9M | |
2.7M | 7.3M | 141.2M | 135.1M | |
0.0 | 202K | 194K | 49K | |
22.8M | 35.1M | 199.3M | 141M | |
SHAREHOLDERS' EQUITY | ||||
605.2M | 575.7M | 8.1M | 5.1M | |
-333.4M | -252.8M | -181.7M | -117.8M | |
278K | 245K | 164K | 167K | |
272.1M | 323.1M | -173.4M | -112.6M | |
272.1M | 323.1M | -173.4M | -112.6M | |
SUMMARY | ||||
294.9M | 358.2M | 25.9M | 28.4M | |
92.3M | 100K | 100K | 0.0 | |
5.6M | 8.7M | 53.3M | 2.5M | |
-183.3M | -345.6M | 31.6M | -25.2M | |
35,850,037 | 35,850,037 | 35,850,037 | 35,850,037 |
BIOA - Filing history and reports
No SEC filings available for BIOA
Continue your BIOA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.